ID: ALA4243901

Max Phase: Preclinical

Molecular Formula: C17H11ClFN3S

Molecular Weight: 343.81

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Fc1cccc(Nc2ncc3c(n2)-c2ccc(Cl)cc2SC3)c1

Standard InChI:  InChI=1S/C17H11ClFN3S/c18-11-4-5-14-15(6-11)23-9-10-8-20-17(22-16(10)14)21-13-3-1-2-12(19)7-13/h1-8H,9H2,(H,20,21,22)

Standard InChI Key:  CVQAYEOLNDZKLH-UHFFFAOYSA-N

Associated Targets(Human)

MSTO-211H 316 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

A-431 6446 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HeLa 62764 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

HUVEC 11049 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Vascular endothelial growth factor receptor 2 20924 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 343.81Molecular Weight (Monoisotopic): 343.0346AlogP: 5.29#Rotatable Bonds: 2
Polar Surface Area: 37.81Molecular Species: NEUTRALHBA: 4HBD: 1
#RO5 Violations: 1HBA (Lipinski): 3HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 12.55CX Basic pKa: 1.51CX LogP: 5.22CX LogD: 5.22
Aromatic Rings: 3Heavy Atoms: 23QED Weighted: 0.69Np Likeness Score: -1.79

References

1. Salerno S, García-Argáez AN, Barresi E, Taliani S, Simorini F, La Motta C, Amendola G, Tomassi S, Cosconati S, Novellino E, Da Settimo F, Marini AM, Via LD..  (2018)  New insights in the structure-activity relationships of 2-phenylamino-substituted benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors.,  150  [PMID:29547832] [10.1016/j.ejmech.2018.03.013]

Source